Identification of fluorescent dyes that label the filamentous protein aggregates characteristic of neurodegenerative disease, such as β-amyloid and tau in Alzheimer's disease, in a live cell culture system has previously been a major hurdle. Here we show that pentameric formyl thiophene acetic acid (pFTAA) fulfills this function in living neurons cultured from adult P301S tau transgenic mice. Injection of pFTAA into 5-month-old P301S tau mice detected cortical and DRG neurons immunoreactive for AT100, an antibody that identifies solely filamentous tau, or MC1, an antibody that identifies a conformational change in tau that is commensurate with neurofibrillary tangle formation in Alzheimer's disease brains. In fixed cultures of dorsal root ganglion (DRG) neurons, pFTAA binding, which also identified AT100 or MC1+ve neurons, followed a single, saturable binding curve with a half saturation constant of 0.14 μM, the first reported measurement of a binding affinity of a beta-sheet reactive dye to primary neurons harboring filamentous tau. Treatment with formic acid, which solubilizes filamentous tau, extracted pFTAA, and prevented the re-binding of pFTAA and MC1 without perturbing expression of soluble tau, detected using an anti-human tau (HT7) antibody. In live cultures, pFTAA only identified DRG neurons that, after fixation, were AT100/MC1+ve, confirming that these forms of tau pre-exist in live neurons. The utility of pFTAA to discriminate between living neurons containing filamentous tau from other neurons is demonstrated by showing that more pFTAA+ve neurons die than pFTAA-ve neurons over 25 days. Since pFTAA identifies fibrillar tau and other misfolded proteins in living neurons in culture and in animal models of several neurodegenerative diseases, as well as in human brains, it will have considerable application in sorting out disease mechanisms and in identifying disease-modifying drugs that will ultimately help establish the mechanisms of neurodegeneration in human neurodegenerative diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448042PMC
http://dx.doi.org/10.3389/fnins.2015.00184DOI Listing

Publication Analysis

Top Keywords

filamentous tau
20
tau
14
neurons
13
p301s tau
12
living neurons
12
drg neurons
12
pftaa
9
pftaa identifies
8
live neurons
8
neurons cultured
8

Similar Publications

Oxidative stress is an important driver of aging and has been linked to numerous neurodegenerative disorders, including Alzheimer's disease. A key pathological hallmark of Alzheimer's are filamentous inclusions made of the microtubule associated protein Tau. Based on alternative splicing, Tau protein can feature either three or four microtubule binding repeats.

View Article and Find Full Text PDF

Corticobasal degeneration: An update.

Ideggyogy Sz

November 2024

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.

Article Synopsis
  • Corticobasal degeneration (CBD) is a progressive tauopathy, typically starting between the ages of 50 and 70, marked by neuronal loss and tau protein deposits in various brain regions.
  • CBD is primarily associated with the corticobasal syndrome (CBS), but can also manifest as other clinical conditions, such as frontotemporal dementia and Richardson's syndrome.
  • Definitive diagnosis of CBD requires neuropathological investigation, as specific biomarkers are currently lacking, although recent studies highlight its unique molecular structure compared to other tauopathies.
View Article and Find Full Text PDF

Tau is a protein involved in the regulation of axonal microtubules in neurons. In pathological conditions, it forms filamentous aggregates which are molecular markers of neurodegenerative diseases known as tauopathies. Structures of Tau in fibrils or bound to the microtubule have been reported.

View Article and Find Full Text PDF

The τ-subunit of the clamp loader complex physically interacts with both the DnaB helicase and the polymerase III (Pol III) core α-subunit through domains IV and V, respectively. This interaction is proposed to help maintain rapid and efficient DNA synthesis rates with high genomic fidelity and plasticity, facilitating enzymatic coupling within the replisome. To test this hypothesis, CRISPR-Cas9 editing was used to create site-directed genomic mutations within the dnaX gene at the C terminus of τ predicted to interact with the α-subunit of Pol III.

View Article and Find Full Text PDF
Article Synopsis
  • Mutations in the tau gene can cause a type of brain disease called frontotemporal dementia and parkinsonism, leading to changes in behavior and thinking.
  • The study focused on two specific mutations, P301L and P301T, found in different people, revealing unique structures of tau proteins in their brains.
  • The researchers suggest that these mutations create special kinds of tau-related brain diseases that should be treated differently in research studies about similar conditions.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!